NCT01020864

Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer

Phase II Trial of Cetuximab in Combination With Chemotherapy (Carboplatin and Navelbine) for Patients With Platinum-resistant Head and Neck Cancer

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Per Pfeiffer · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an open, multicenter phase II study. The purpose is to demonstrate the efficacy of cetuximab in combination with carboplatin and vinorelbine as second line treatment in patients with recurrent or metastatic head and neck cancer who have progressed during or after treatment with first line cisplatinum.

Conditions

• Head and Neck Neoplasms

Interventions

Type	Name	Description
DRUG	Cetuximab	Cetuximab 500 mg/m² i.v. day 1, every 2nd week
DRUG	Carboplatin	Carboplatin AUC = 3 i.v. day 1, every 21nd week
DRUG	Vinorelbine	Vinorelbine 25 mg/m² i.v. day 1, every 2nd week

Timeline

• Start date: 2010-01-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2009-11-26
• Last updated: 2020-11-02

Locations

1 site across 1 country: Denmark